Key result
Gene-based therapy targeting β-adrenergic receptor signaling, Ca(2+) handling proteins, and angiogenesis holds potential as a targeted treatment for diverse models of heart failure.
This review surveys the therapeutic efficacy of gene therapy targeting specific molecular pathways in various extrinsic models of heart failure.
Heart failure (HF) is a complex multifaceted problem of abnormal ventricular function and structure. In recent years, new information has been accumulated allowing for a more detailed understanding of the cellular and molecular alterations that are the underpinnings of diverse causes of HF, including myocardial ischemia, pressure-overload, volume-overload or intrinsic cardiomyopathy. Modern pharmacological approaches to treat HF have had a significant impact on the course of the disease, although they do not reverse the underlying pathological state of the heart. Therefore gene-based therapy holds a great potential as a targeted treatment for cardiovascular diseases. Here, we survey the relative therapeutic efficacy of genetic modulation of β-adrenergic receptor signaling, Ca(2+) handling proteins and angiogenesis in the most common extrinsic models of HF.
No takes yet. Share an insight, caveat, or question.
Katz et al. (2011) conducted a review in Heart failure. Gene-based therapy was evaluated. Gene-based therapy targeting β-adrenergic receptor signaling, Ca(2+) handling proteins, and angiogenesis holds potential as a targeted treatment for diverse models of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: